The company has since learned the cyberattack was caused by a third-party contractor’s user session within its cloud-based system being compromised.
Xeltis has reached over 50% enrolment in its US pivotal trial of aXess, a vascular access device designed for adults with end-stage renal disease who require haemodialysis.
The test is designed for individuals aged 45 and above who are at average risk for cancer. Credit: tilialucida / Shutterstock.com. Zydus Lifesciences has entered a memorandum of understanding (MoU) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results